The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...

Lorna Staines discusses a longitudinal population-based study examining the risks of using psychedelics in a naturalistic ...

The connection between M. morganii, inflammation, and depression aligns with earlier research. IL-6 has been repeatedly ...